Glucagon/GLP-1 receptor co-agonists
Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (K-RNRNNIA) and SEQ ID NO: 28 (KRNR).
1. An isolated peptide consisting essentially of the sequence of SEQ ID NO: 510, or a pharmaceutically acceptable salt thereof.
2. The isolated peptide of claim 1 , wherein the Cys at position 24 of SEQ ID NO: 510 is attached to a polyethylene glycol of about 40 kDa average weight.
3. A pharmaceutical composition comprising an isolated peptide consisting essentially of the sequence of SEQ ID NO: 510, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 2 , wherein the Cys at position 24 of SEQ ID NO: 510 is attached to a polyethylene glycol of about 40 kDa average weight.
5. An isolated peptide consisting of the sequence of SEQ ID NO: 510, or a pharmaceutically acceptable salt thereof.
6. The isolated peptide of claim 5 , wherein the Cys at position 24 of SEQ ID NO: 510 is attached to a polyethylene glycol of about 40 kDa average weight.
7. A pharmaceutical composition comprising an isolated peptide consisting of the sequence of SEQ ID NO: 510, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
8. The pharmaceutical composition of claim 7 , wherein the Cys at position 24 of SEQ ID NO: 510 is attached to a polyethylene glycol of about 40 kDa average weight.